Replies to post #57998 on Branded Legacy Inc (BLEG)

[Gnarlyman]

I like the fact Dave said the new guy Dr.Hamman is already preparing a path to submit a clinical trial for the Kratom drug they’ve been working on.

I had not researched this dudes creds really until yesterday. He’s not a lightweight in his field.

Biography

Dr. Mark T. Hamann serves as the Charles and Carol Cooper/SmartState Endowed Chair of Drug Discovery, Biomedical Sciences and Public Health at the MUSC Colleges of Pharmacy and Medicine. He also holds Adjunct appointments with The University of Maryland’s Institute of Marine and Environmental Technology and the Bigelow Marine Laboratory in Maine. Dr. Hamann began his career in cGMP pharmaceutical manufacturing at Solvay Pharmaceuticals in Baudette, Minnesota and then completed a Ph.D. degree in Organic Chemistry at the University of Hawaii, under the guidance of the late Professor Paul J. Scheuer. During his graduate studies he discovered the lead anticancer agent, kahalalide F which entered clinical trials with the help of the biotech company PharmaMar. Dr. Hamann completed Postdoctoral Studies with Prof Bill Baker at McMurdo Station in Antarctica and then spent 20 years as a faculty member and natural products researcher at The University of Mississippi School of Pharmacy. During his research career, Dr. Hamann has published over 250 scientific papers, reviews, book chapters and guided over 100 graduate students/postdoctoral fellows and visiting scholars. Dr. Hamann served as an Associate Editor for Biochimica et Biophysica Acta, General Subjects. Dr. Hamann with the aid of his students, has received a number of awards including an NIH New Investigator Award (R29) and a Career Development Award (KO2) from NIAID, an American Society of Pharmacognosy Young Investigator Award, The American Foundation for Pharmaceutical Education, Pharmacy Faculty New Investigator Award and The University of Mississippi, School of Pharmacy, Researcher of the Year Award. His group is actively involved in the isolation, structure determination and optimization of natural products and toxins with a focus on plant and invertebrate microbiomes. His group is currently working on the preclinical development of a small pipeline of natural products with activity against cancer, emerging infectious diseases and neuropsychiatric disorders. Dr. Hamann’s laboratory has worked on the optimization of processing methods and synthetic optimization of the chemical structures of the cannabinoids for potential applications in the control of pain, cancer and infectious diseases.